Dengue Fever Vaccine Study
An exciting research study, the Dengue Fever Vaccine Study aims to test the effectiveness and safety of an experimental vaccine for the prevention of dengue fever. A different lot of this vaccine was previously tested in another trial and was generally well-tolerated. This current research trial will evaluate a new lot of this vaccine and the results will be compared with those of the previous trial.
The study has been designed for maximum volunteer safety and has been approved by the U.S. Food and Drug Administration (FDA), the UVM Institutional Review Board (IRB) and the UVM Biosafety Committee (IBC).
Dengue fever is rare in the United State, but is common in most tropical and subtropical regions of the world. Dengue virus is an RNA virus that is transmitted by the Aedes egypti mosquito and can cause significant febrile illness, commonly called Dengue Fever. Most individuals spontaneously recover from primary infection; however, secondary infections are more frequently associated severe complications, including shock and bleeding disorders. Dengue viruses cause 50-100 million infections each year, with roughly 500,000 hospitalizations. Although most infections occur in tropical and subtropical areas, global warming has increased the possibility of Dengue becoming a significant risk in areas not previoulsy impacted by the disease, including the United States. The development of Dengue vaccines is a priority of the National Institutes of Health. Work on dengue vaccines is a new direction for the laboratory and Vaccine Testing Center. Over the last three years, the VTC lab has been working with collaborators to better define cellular immune responses to live, attenuated dengue vaccines. This work will continue for the next couple of years here at the Vaccine Testing Center and we hope that this research study will lead to a vaccine that will protect human populations against this viral infection.
Last modified March 03 2016 02:44 PM